RE:RE:RE:RE:okayWith respect, you are totally wrong. Virology on its own will never move the stock price beyond where it is now. We need one of the pipelines tied to a monetary agreement with royalty payments to move the price with sustainability. Virusmax, Urokinase, and especially Lumisort would independently provide the needed catalyst. As of yet we just don't have needed monetary agreement. The market was expecting something this Q, didn't get it and overreacted accordingly. Agreements will never be announced on an official Q report. A Q report is used to report the financial results over the previous 3 months. Key material events such as signed agreements are announced immediately irrespective of when the next Q report is scheduled. This last sell-off of 1.5million shares was a protest move in response to a lack of any monetary agreement. JMHO